RxDoctor Payments Data

Vasti Zapata

Nurse Practitioner · McAllen, TXNPI 1407387178

Payments from drug & device makers

$1,075in general payments, 2019–2025

Across 41 payments — averaging $26.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$317
  • AbbVie$243
  • AstraZeneca$139
  • Lilly USA, LLC$137
  • Redhill Biopharma Inc.$95
  • Astellas Pharma US Inc$62
  • plus $82 from 5 others

What the payments were for

  • Food & beverage$1,01394%
  • Education$626%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,075 in reported general payments places this provider in the 75th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$41,255
Medicare patients
202
Services billed
801

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron21$25,927
FarxigaDapagliflozin Propanediol20$19,490
JardianceEmpagliflozin14$18,967
MounjaroTirzepatide15$18,858
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$18,507
TrulicityDulaglutide11$16,658
LinzessLinaclotide13$11,010
Breo ElliptaFluticasone/Vilanterol14$5,246
Pregabalin63$1,836
Albuterol Sulfate HfaAlbuterol Sulfate29$1,084
Diclofenac Sodium43$1,040
Clonazepam20$978
Atorvastatin Calcium63$800
Alprazolam126$761
Fluticasone Propionate64$743

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$137$35,51526 claims
Astellas Pharma US IncMyrbetriq$62$25,92721 claims
AstraZenecaFarxiga$139$19,49020 claims
Boehringer IngelheimJardiance$14$18,96714 claims
AbbVieLinzess$243$11,01013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →